SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan
SOPHiA GENETICS SA - Ordinary Shares (SOPH)
Company Research
Source: PR Newswire
The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEOBOSTON and ROLLE, Switzerland, Jan. 12, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited financial results for the fourth quarter and full year 2025, initiated its financial outlook for 2026, and announced an executive transition plan, including the promotion of Ross Muken to Chief Executive Officer (CEO), effective July 1, 2026, and the transition of co-Founder Jurgi Camblong to Executive Chairman.Fourth Quarter 2025 Preliminary Unaudited Financial ResultsRevenue of at least $21 million, representing an increase of approximately 20% year-over-yearPerformed over 105,000 analyses on SOPHiA DDM™ in the fourth quarter, representing 16% year-over-year growthFull Year 2025 Preliminary Unaudited Financial ResultsRevenue of approximately $77 million, representing an increase of appr
Show less
Read more
Impact Snapshot
Event Time:
SOPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SOPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SOPH alerts
High impacting SOPHiA GENETICS SA - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
SOPH
News
- SOPHiA GENETICS verstrekt voorlopige financiële resultaten voor het vierde kwartaal en het volledige jaar 2025, geeft richtsnoeren voor 2026 en kondigt overgangsplan voor de directie aanPR Newswire
- SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition PlanPR Newswire
- SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision OncologyPR Newswire
- Complete Genomics and SOPHiA GENETICS Announce Integration of MSK-IMPACT® and MSK-ACCESS® Assays on DNBSEQ-T1+ Platform at AMP 2025 [Yahoo! Finance]Yahoo! Finance
- Complete Genomics and SOPHiA GENETICS Announce Integration of MSK-IMPACT® and MSK-ACCESS® Assays on DNBSEQ-T1+ Platform at AMP 2025PR Newswire
SOPH
Earnings
- 5/6/25 - Miss
SOPH
Analyst Actions
- 11/10/25 - BTIG
SOPH
Sec Filings
- 1/16/26 - Form 144
- 1/12/26 - Form 6-K
- 1/12/26 - Form 6-K
- SOPH's page on the SEC website